Scientists worldwide committed to develop vaccines against 2019 n-CoV
Scientists worldwide accelerate efforts in laboratory researches to develop vaccines against 2019 n-CoV after WHO declared a global health emergency, consequence to the spreading of the deadly virus.
Scientists from the United States to Australia are using new technology in an ambitious, multi-million-dollar drive to develop a vaccine in record time to tackle China’s coronavirus outbreak.
Coming up with any vaccine typically takes years, and involves a lengthy process of testing on animals, clinical trials on humans and regulatory approvals.
However several teams of experts are racing to develop one quicker, backed by an international coalition that aims to combat emerging diseases. Australian scientists hope theirs could be ready in six months.
The Coalition for Epidemic Preparedness Innovations (CEPI), a body established in 2017 which works to develop vaccines against emerging infectious diseases, are currently funding costly biotechnology research to develop vaccine for use against 2019 n-CoV.
German biopharmaceutical company CureVac and US-based Moderna Therapeutics are developing vaccines based on “messenger RNA” — instructions that tell the body to produce proteins — while Inovio, another American firm, is using DNA-based technology.
The Australian researchers are using “molecular clamp” technology invented by the university’s scientists that allows them to rapidly develop new vaccines based solely on a virus DNA sequence.
French scientists at the Pasteur Institute are modifying the measles vaccine to work against the coronavirus, but do not expect it to be ready for about 20 months.
Meanwhile, the Chinese Centre for Disease Control and Prevention has also started developing vaccines.